Literature DB >> 16448726

pDNAVACCultra vector family: high throughput intracellular targeting DNA vaccine plasmids.

James A Williams1, Jeremy Luke, Lance Johnson, Clague Hodgson.   

Abstract

DNA vaccines have the potential to provide a safe route for protective immunity to neoplasms and infectious agents. However, current DNA vaccine plasmids are not optimal with additional non-essential DNA, nor do they facilitate controlled or flexible targeting of antigens to various intracellular destinations. A family of DNA vaccine vectors, optimized and minimized to comply with FDA guidelines regarding content and elimination of extraneous materials, was constructed. The resulting vectors are much smaller than existing vectors, drive higher levels of target gene expression, facilitate high throughput cloning applications, and allow simultaneous cloning into multiple vectors that feature various intracellular targeting destinations for the protein product. The ability to control expression and trafficking is intended to provide a rapid, rational approach to cancer therapy and emerging infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16448726     DOI: 10.1016/j.vaccine.2005.08.033

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

Review 2.  Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA.

Authors:  Juergen Mairhofer; Reingard Grabherr
Journal:  Mol Biotechnol       Date:  2008-06       Impact factor: 2.695

3.  Sequential immunization induces strong and broad immunity against all four dengue virus serotypes.

Authors:  Jue Hou; Shubham Shrivastava; Hooi Linn Loo; Lan Hiong Wong; Eng Eong Ooi; Jianzhu Chen
Journal:  NPJ Vaccines       Date:  2020-07-24       Impact factor: 7.344

4.  Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.

Authors:  Zahra Heidari; Jaspreet S Arora; Dibyadyuti Datta; Vijay T John; Nirbhay Kumar; Geetha P Bansal
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

5.  Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields.

Authors:  Aaron E Carnes; Jeremy M Luke; Justin M Vincent; Sheryl Anderson; Angela Schukar; Clague P Hodgson; James A Williams
Journal:  J Gene Med       Date:  2010-10       Impact factor: 4.565

Review 6.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

7.  Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes.

Authors:  James A Williams; Jeremy Luke; Sarah Langtry; Sheryl Anderson; Clague P Hodgson; Aaron E Carnes
Journal:  Biotechnol Bioeng       Date:  2009-08-15       Impact factor: 4.530

8.  Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system.

Authors:  Jeremy Luke; Aaron E Carnes; Clague P Hodgson; James A Williams
Journal:  Vaccine       Date:  2009-06-24       Impact factor: 3.641

9.  Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Ulrike Gerdemann; Juan F Vera; Cliona M Rooney; Ann M Leen
Journal:  J Vis Exp       Date:  2011-05-27       Impact factor: 1.355

Review 10.  Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.

Authors:  James A Williams
Journal:  Vaccines (Basel)       Date:  2013-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.